Selection of Derek H. Lee, formerly of SV Lifesciences, as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model Talaris to leverage Lee's venture capital expertise with more than 55 portfolio therapeutics, medical device and healthcare services companies.
Hopkinton, MA, March 8, 2010 - Talaris Advisors, LLC, today announced the appointment of Derek H.Lee to the role of Chief Financial and Corporate Development Officer. Mr. Lee comes to Talaris from SV Life Sciences (SVLS), a leading healthcare venture capital firm with capital commitments of approximately $1.5 billion. He was responsible for directing strategic financial and investment planning that incorporated market considerations into the operational performance and financing requirements of more than 55 portfolio therapeutics, medical device and healthcare services companies.
"We are entering a new phase of biotech and pharma investment today where success will be determined by a company's ability to make smart analytical decisions about its drug development candidates and terminate programs early and quickly when they miss key competitive and capital indicators," commented Mark J. Pykett, Chief Executive Officer. "In this regard, Derek brings a strong investor perspective to our operations. His experience in aligning development with exit strategies and realizing optimal exits are a key component of Talaris' value proposition. As our Chief Financial and Corporate Development Officer, Derek's ability to conduct quantitative and qualitative analyses, identify key risks and opportunities in complex financial and valuation models, and facilitate negotiations will give us the corporate vantage point our valued clients and investors need." Derek brings a decade's worth of expertise in ensuring some of the best management teams in the industry achieved their investment objectives. His background includes a range of experiences, from private and public financing strategies, to M&A transactions, partnerships and deal structuring. Lee has prior experience working with the Global Healthcare Group at UBS Warburg and with the Healthcare Investment Banking Group at Salomon Smith Barney. He received his BS Finance from Bentley College.
ABOUT TALARIS ADVISORS, LLC Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts.
Please visit Talaris at www.talarisadvisors.com.
Media Contact: Vicki Byatte Talaris Advisors Telephone: 508-497-2300 x 229 Email: [email protected]